355 related articles for article (PubMed ID: 22186319)
1. Glycemic control, dyslipidemia and endothelial dysfunction in coexisted diabetes, hypertension and nephropathy.
Shahid SM; Nawab SN; Shaikh R; Mahboob T
Pak J Pharm Sci; 2012 Jan; 25(1):123-9. PubMed ID: 22186319
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum nitric oxide and sialic acid in coexisted diabetes, hypertension and nephropathy.
Shahid SM; Jawed M; Mahboob T
Pak J Pharm Sci; 2013 May; 26(3):593-7. PubMed ID: 23625435
[TBL] [Abstract][Full Text] [Related]
3. Relationship between sialic acid and metabolic variables in Indian type 2 diabetic patients.
Nayak SB; Bhaktha G
Lipids Health Dis; 2005 Aug; 4():15. PubMed ID: 16092968
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Diabetic Nephropathy by Circulating Gangliosides.
Ene CD; Penescu M; Anghel A; Neagu M; Budu V; Nicolae I
J Immunoassay Immunochem; 2016; 37(1):68-79. PubMed ID: 26359623
[TBL] [Abstract][Full Text] [Related]
5. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
Abdin AA; Hassanien MA; Ibrahim EA; El-Noeman Sel-D
J Diabetes Complications; 2010; 24(5):325-33. PubMed ID: 19553142
[TBL] [Abstract][Full Text] [Related]
6. Glycemic status, lipid profile and proteinuria in diabetic nephropathy.
Jha P; Das BK; Shrestha S; Majhi S; Chandra L; Sharma S; Baral N
JNMA J Nepal Med Assoc; 2010; 49(178):143-6. PubMed ID: 21485601
[TBL] [Abstract][Full Text] [Related]
7. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study.
Crook MA; Pickup JC; Lumb PJ; Giorgino F; Webb DJ; Fuller JH;
Diabetes Care; 2001 Feb; 24(2):316-22. PubMed ID: 11213885
[TBL] [Abstract][Full Text] [Related]
8. Triglyceride-glucose index: A surrogate marker of homeostasis model assessment of insulin resistance to predict diabetic nephropathy.
Khan S; Qayyum S; Khan MNA
J Pak Med Assoc; 2024 May; 74(5):862-867. PubMed ID: 38783431
[TBL] [Abstract][Full Text] [Related]
9. Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy.
Yokoyama H; Jensen JS; Jensen T; Deckert T
J Intern Med; 1995 May; 237(5):519-23. PubMed ID: 7738493
[TBL] [Abstract][Full Text] [Related]
10. Serum lipids and the progression of nephropathy in type 1 diabetes.
Thomas MC; Rosengård-Bärlund M; Mills V; Rönnback M; Thomas S; Forsblom C; Cooper ME; Taskinen MR; Viberti G; Groop PH
Diabetes Care; 2006 Feb; 29(2):317-22. PubMed ID: 16443880
[TBL] [Abstract][Full Text] [Related]
11. Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus.
Dejenie TA; Abebe EC; Mengstie MA; Seid MA; Gebeyehu NA; Adella GA; Kassie GA; Gebrekidan AY; Gesese MM; Tegegne KD; Anley DT; Feleke SF; Zemene MA; Dessie AM; Moges N; Kebede YS; Bantie B; Adugna DG
Front Endocrinol (Lausanne); 2023; 14():1124367. PubMed ID: 37082121
[TBL] [Abstract][Full Text] [Related]
12. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy.
Chen J; Gall MA; Yokoyama H; Jensen JS; Deckert M; Parving HH
Diabetes Care; 1996 Feb; 19(2):130-4. PubMed ID: 8718432
[TBL] [Abstract][Full Text] [Related]
13. Relationship between periodontal status and dyslipidemia in patients with type 2 diabetic nephropathy and chronic periodontitis: A cross-sectional study.
Zhang D; Zhao C; Liu Z; Ding Y; Li W; Yang H; Wang Z; Li Y
J Periodontal Res; 2022 Oct; 57(5):969-976. PubMed ID: 35848007
[TBL] [Abstract][Full Text] [Related]
14. The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy.
Lv C; Zhou YH; Wu C; Shao Y; Lu CL; Wang QY
Diabetes Metab Res Rev; 2015 Oct; 31(7):717-24. PubMed ID: 25952368
[TBL] [Abstract][Full Text] [Related]
15. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus.
Artha IMJR; Bhargah A; Dharmawan NK; Pande UW; Triyana KA; Mahariski PA; Yuwono J; Bhargah V; Prabawa IPY; Manuaba IBAP; Rina IK
Vasc Health Risk Manag; 2019; 15():149-157. PubMed ID: 31239693
[No Abstract] [Full Text] [Related]
16. Factors Associated with Poor Glycemic and Lipid Levels in Ambulatory Diabetes Mellitus Type 2 Patients in Asmara, Eritrea: A Cross-Sectional Study.
Achila OO; Ghebretinsae M; Kidane A; Simon M; Makonen S; Rezene Y
J Diabetes Res; 2020; 2020():5901569. PubMed ID: 32090121
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic control and microvascular complications in a large cohort of Italian Type 1 diabetic out-patients.
Lepore G; Bruttomesso D; Nosari I; Tiengo A; Trevisan R
Diabetes Nutr Metab; 2002 Aug; 15(4):232-9. PubMed ID: 12416660
[TBL] [Abstract][Full Text] [Related]
18. Excessive visit-to-visit glycemic variability independently deteriorates the progression of endothelial and renal dysfunction in patients with type 2 diabetes mellitus.
Wei F; Sun X; Zhao Y; Zhang H; Diao Y; Liu Z
BMC Nephrol; 2016 Jul; 17(1):67. PubMed ID: 27386849
[TBL] [Abstract][Full Text] [Related]
19. The link between diabetic retinal and renal microvasculopathy is associated with dyslipidemia and upregulated circulating level of cytokines.
Chen X; Zhang X; Gong Z; Yang Y; Zhang X; Wang Q; Wang Y; Xie R
Front Public Health; 2022; 10():1040319. PubMed ID: 36733289
[TBL] [Abstract][Full Text] [Related]
20. Glycemic control predicts diabetic extrarenal microvascular complications but not renal survival in patients with moderate to severe chronic kidney disease.
Crook ED; Patel S
Ethn Dis; 2006; 16(4):865-71. PubMed ID: 17061739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
